A
Arnon Nagler
Researcher at Sheba Medical Center
Publications - 1435
Citations - 51740
Arnon Nagler is an academic researcher from Sheba Medical Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 98, co-authored 1316 publications receiving 44298 citations. Previous affiliations of Arnon Nagler include French Institute of Health and Medical Research & University of Paris.
Papers
More filters
Journal ArticleDOI
BL-8040 CXCR4 antagonist is safe and demonstrates antileukemic activity in combination with cytarabine for the treatment of relapsed/refractory acute myelogenous leukemia: An open-label safety and efficacy phase 2a study.
Gautam Borthakur,Yishai Ofran,Martin S. Tallman,James M. Foran,Geoffrey L. Uy,John F. DiPersio,Margaret M. Showel,Avichai Shimoni,Arnon Nagler,Jacob M. Rowe,Jessica K. Altman,Michal Abraham,Amnon Peled,Stephen Shaw,Osnat Bohana-Kashtan,Ella Sorani,Yaron Pereg,Adam Foley-Comer,Galia Oberkovitz,Tzipi Lustig,Irit Glicko-Kabir,Arnon Aharon,Abi Vainstein-Haras,Shaul Kadosh,Emil Samara,Ahmed AlRawi,Naveen Pemmaraju,Carlos E. Bueso-Ramos,Jorge E. Cortes,Michael Andreeff +29 more
TL;DR: The authors evaluated a combination of the high‐affinity CXCR4 antagonist BL‐8040 with high‐dose cytarabine (HiDAC) chemotherapy in a phase 2a study of patients with relapsed and refractory AML.
Journal ArticleDOI
Umbilical cord blood for use in transplantation
TL;DR: The developments in this field which have occurred during the last decade, as well as the importance of cooperation between the obstetric and transplantation staff, are discussed in this review.
Journal ArticleDOI
Fludarabine and treosulfan compared with other reduced-intensity conditioning regimens for allogeneic stem cell transplantation in patients with lymphoid malignancies
Ronit Yerushalmi,Noga Shem-Tov,Ivetta Danylesko,Abraham Avigdor,Arnon Nagler,Avichai Shimoni +5 more
TL;DR: FB2 is associated with low NRM and good results in chemo-sensitive disease, but with higher relapse mortality rates, and is as safe as FB2 and as cytoreductive as FM, resulting in improved outcome, mostly in advanced disease.
Journal ArticleDOI
Genetic susceptibility to Hodgkin's lymphoma and to secondary cancer: Workshop report
TL;DR: The finding that particular human leukocyte antigen (HLA) alleles are associated with susceptibility to HL may be regarded as a hint to the presence of an as yet undefined infectious agent, leading to the growth of a malignant lymphoma cell clone in patients that are more susceptible to this agent due to their HLA genotype.
Journal ArticleDOI
Secondary refractory anemia with excess of blasts in transformation terminating as acute lymphoblastic leukemia.
TL;DR: A case of refractory anemia with an excess of blasts in transformation, secondary to irradiation, and leading ultimately to acute lymphoblastic leukemia, is presented.